anacetrapib
Sign in to saveAlso known as MK-0859
Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.
Research
268 papersvia PubMed
Wikidata facts
- Mass
- 637.167476
Show 3 more facts
- chemical formula
- C₃₀H₂₅F₁₀NO₃
- isomeric SMILES
- C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
- canonical SMILES
- CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
Sources (2)
via Wikidata · CC0
~1 min read
Article
4 sectionsContents
- Evidence
- See also
- References
- Further reading
{{chembox | Verifiedfields = changed | verifiedrevid = 444391072 | ImageFile = Anacetrapib.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4′-fluoro-2′-methoxy-5′-(propan-2-yl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one | OtherNames = MK-0859 |Section1= |Section2= |Section3= }} Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.
==Evidence== In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.
Available in 9 languages
via Wikidata sitelinks · CC0